IL2 and metastatic melanoma: Robbins et al. [118] conducted a phase II trial with letetresgene autoleucel (Lete-cel), a therapy based on T cells transduced with a TCR against NY-ESO1, plus adjuvant IL-2- in HLA-A02 patients with metastatic melanoma and synovial sarcoma.